Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (April 2025)
30 slides from Adocia Sa's investor presentation, Apr 1, 2025
Slide 1: ADOCIA Presentation April 2025
ADOCIA Presentation April 2025
Slide 2: Forward-looking statements
Forward-looking statements ADOC This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall m
Slide 3: Renewed management team
Renewed management team Olivier Soula Mathieu-William Gilbert PhD, MBA CEO Chief Financial Officer Co-founder Chief Operating Officer Leading a team of 80 experts, including 35 PhDs/MDs/PharmDs, based in Lyon, France 3 3
Slide 4: Diabetes and Obesity: Chronic pandemics due to peptide dysregulation
Diabetes and Obesity: Chronic pandemics due to peptide dysregulation Metabolic diseases Peptides dysregulation Peptide Due Insulin Treated Replacement Therapies Diabetes to Amylin by 537 million1 GLP-1 Efficient Obesity Glucagon Safe 1.9 billion2 … Delivery Challenges To address Peptides are ephemer
Slide 5: 4 proprietary platforms designed to unleash peptide-delivery in chronic diseases
4 proprietary platforms designed to unleash peptide-delivery in chronic diseases Peptides combinations BioChaperone® Improving efficacy with synergistic Mechanisms of Action Oral delivery of peptides AdOral® Avoiding injections and facilitating industrialization Long-acting delivery of peptides AdoG
Slide 6: Demonstrated ability to invent, develop up to late stage and partner
Demonstrated ability to invent, develop up to late stage and partner Targeted Indications Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner Phase 3 readout H1 2025 PARTNERED BioChaperone® DIABETES $20m at Marketing Approval in China Lispro Double-Digit Royalties Exclusive negoti
Slide 7: Upcoming major inflexion points potentially transforming value
Upcoming major inflexion points potentially transforming value BioChaperone® Amylin-GLP1 Combining next-gen obesity 1 products 2025 Formulation achieved on CagriSema and potential partnership M1Pram 2 Major partnership Licensing discussions w. Sanofi and, once discussions completed, launch of Phase
Slide 8: BioChaperone CagriSema
Diabetes & Obesity BioChaperone® CagriSema Combining peptides for greater and better weight loss 8 8
Slide 9: BioChaperone: designed to improve obesity drugs through peptide co-formulation
BioChaperone®: designed to improve obesity drugs through peptide co-formulation CagriSema 4 double-chamber pens 1 multi-use pen + /month /month Single-use double-chamber pen • Novo Nordisk Cagrilintide Semaglutide • Phase 3: obesity, diabetes • -22% weight loss/year BioChaperone® + ✓ Clinically test
Slide 10: M1Pram: Insulin + Amylin analogs combination
Back Cover Diabetes & Obesity M1Pram Insulin + Amylin analogs combination To treat obesity in insulin-dependent people In exclusive negotiation with 10 10
Slide 11: Obesity in people with T1D is dramatically growing
Obesity in people with T1D is dramatically growing However, marketed obesity drugs are not approved in this population BMI3 in people with T1D1 Diabetes WEIGHT: INSULIN: In the U.S., people with T1D2 • Obesity (BMI≥30kg/m2): 40% INSULIN WEIGHT • Overweight (BMI≥25kg/m2): 70% Obesity Adocia is de
Slide 12: M1Pram: insulin and amylin combination to control glycemia and lose weight
M1Pram: insulin and amylin combination to control glycemia and lose weight Gold Standard Mealtime Insulin M1Pram = Insulin + Amylin Same number and time of injections Targeting: Same glycemic control Same risk of hypoglycemia Same local tolerance Goals: Weight Gain Equivalent Weight Loss to gold sta
Slide 13: M1Pram reduced body weight in T1D with obesity in Phase 2 trial
M1Pram reduced body weight in T1D with obesity in Phase 2 trial1 comparable to data reported for GLP-1 in T2D M1Pram in people with T1D – head-to-head vs. Humalog Marketed obesity drugs in T2D taking basal insulin BW Change from baseline at W16 Closest comparison – as GLP-1 not approved in T1D Insul
Slide 14: AdoShell Islets
Diabetes AdoShell® Islets A potential functional cure for Type 1 Diabetes with islets transplantation without immunosuppression 14 14
Slide 15: Current islets transplantation faces challenges, drastically restricting its use
Current islets transplantation faces challenges, drastically restricting its use Immunosuppressants to avoid graft rejection is a high safety concern Cells from deceased donors are in short supply iPSCs under development present a risk of uncontrolled development AdoShell® aims to unlock the potenti
Slide 16: AdoShell Islets: the promise of cell therapy without immunosuppression
AdoShell® Islets: the promise of cell therapy without immunosuppression for people with Type 1 Diabetes Immuno-isolation AdoShell® Islets Ab, T cells Large entities >10nm Therapeutic goals: Allow insulin secretion in response of glycemic variation Protect cells from immune system Minimally invasive
Slide 17: AdoShell Islets has demonstrated immuno-protection and functionality in vivo
AdoShell® Islets has demonstrated immuno-protection and functionality in vivo Transplantation of AdoShell containing allogenic islets in diabetic rat peritoneum at day 0 Sacrifice of control group at day 35 Explantation of the implant at day 132 First in Human planned for H2 2025 17 17
Slide 18: BioChaperone Lispro
Diabetes BioChaperone® Lispro Ultra-Rapid Insulin for a tighter glycemic control Partnered with 18 18
Slide 19: BioChaperone Lispro, potential better efficacy vs. Humalog
BioChaperone® Lispro, potential better efficacy vs. Humalog Post-meal glycaemia in T1D AUC0-2h -61%* Potentially better efficacy profile for fewer hyperglycemia and fewer hypoglycemia (“Faster-in” / “Faster-out”) Good tolerance observed to date (11 clinical trials) Range of strengths (U100 & U200),
Slide 20: China Phase 3 clinical part completed, filing under preparation
China Phase 3 clinical part completed, filing under preparation Partnered with Tonghua Dongbao Licensed for development & commercialization for China and other Asian territories1: $10m upfront $5m milestone - 1st patient on the Phase 3 trial in China $10m milestone - Phase 3 Last Patient Last Visit,
Slide 21: AdOral
Diabetes & Obesity AdOral® Oral delivery of peptides to avoid injections and to facilitate industrialization 21 21
Slide 22: AdOral, a proprietary oral delivery technology for peptides
AdOral®, a proprietary oral delivery technology for peptides 4. The permeation 1. Gastro-resistant galenic Peptide PE enhancer (PE) works by PI solid form Proteases increasing paracellular absorption across the intestinal epithelium Closed TJ 2. Solid form dissolves at neutral pH Open Tight Junction
Slide 23: AdOral has been validated on semaglutide and shows improved bioavailability in animal model
AdOral® has been validated on semaglutide and shows significantly improved bioavailability in animal model Median Semaglutide 14mg PK Profile (N=10 dogs) Reduced API quantity to deliver the therapeutic dose Manufacturing 2.5-fold higher Industrial advantages vs. sterile cost median than injectable
Slide 24: AdoGel
Diabetes & Obesity AdoGel Long-acting formulation to reduce the number of injections 24 24
Slide 25: AdoGel Sema, an investigational once-monthly formulation of semaglutide
AdoGel Sema, an investigational once-monthly formulation of semaglutide AdoGel Sema Injectable Pharmacokinetic in rats + + • No burst Polymer 1 Polymer 2 Semaglutide • Low Cmax Gel Cross-linking reaction + Emulsification + formation between polymers 1 and 2 Polymer 1 Polymer 2 Drug Crosslinked hydro
Slide 26: AdoGel, an injectable hydrogel for sustained release of peptides
AdoGel , an injectable hydrogel for sustained release of peptides Potentially to move from weekly to monthly or Next steps: quarterly injections: Proof of Concept on AdoGel Sema on big animals ongoing Overcomes the need for repeated drug administration Avoids an initial concentration peak IP: Patent
Slide 27: Financials & Conclusions
Financials & Conclusions 27 27
Slide 28: Key Financials
Key Financials • Cash position (Dec. 31, 2024): €7.5 million Shareholder ownership1 • €9.7 million Private Placement completed on Feb. 26, 2025 • $10m milestone payment to be received in Q2 2025 Soula Family & Employees Pool → Cash runway: Q2 2026 10.7% • Indebtedness: €4.5m (state-guaranteed loan m
Slide 29: Adocia at a glance
Adocia at a glance 1 Mission: to develop innovative peptide formulations for diabetes and obesity treatment Business model: Licensing-out our products and technologies after proof of concept 2 2 partners: Tonghua Dongbao (BC Lispro, licensed for Asia) Sanofi (exclusive option on M1Pram – ongoing dis
Slide 30: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com